The main objectives of erectile dysfunction (ED) management are to control and reduce associated organic cardiovascular risk factors and to restore the capacity to obtain and maintain a rigid penile erection.
Since oral phosphodiesterase (PDE)-5 inhibitors have a demonstrated efficiency in the number and duration of erections in patients with ED with a favourable benefit-to-risk ratio, they have been recommended in European guidelines as the first-line medical therapy for ED.
In January 2016, we published a comprehensive review and meta-analysis on the safety and efficacy of avanafil, a novel second-generation PDE-5 inhibitor. This review aims to shed a special spotlight on the key aspects of this meta-analysis and to discuss how avanafil can provide an added value in the management of ED over first-generation agents.
Please view the full content in the pdf above.